INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED
領航醫藥及生物科技有限公司
(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)
(Stock Code: 399)

SUPPLEMENTAL ANNOUNCEMENT

ISSUE OF NEW SHARES UNDER GENERAL MANDATE; AND RESUMPTION OF TRADING

Reference is made to the announcement of the Company dated 15 July 2025 (the "**Announcement**") in relation to the subscription of 60,000,000 shares and 30,000,000 shares of the Company by Zhang Biaobing and Chen Jing, respectively, at the subscription price of HK$0.312 per subscription share pursuant to the subscription agreements both dated 15 July 2025. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as defined in the Announcement.

THE SUPPLEMENTAL AGREEMENTS

The Company would like to supplement that on 16 July 2025, the Company entered into a supplemental agreement with Subscriber A ("**Supplemental Agreement A**") and a supplemental agreement with Subscriber B ("**Supplemental Agreement B**", collectively with Supplemental Agreement A, the "**Supplemental Agreements**"), pursuant to which each of Subscription Price A and Subscription Price B has been revised to HK$0.3124 per Subscription Share A ("**Revised Subscription Price A**") and HK$0.3124 per Subscription Share B ("**Revised Subscription Price B**"), respectively.

Revised Subscription Price A and Revised Subscription Price B

Each of Revised Subscription Price A and Revised Subscription Price B represents:

(i) a discount of approximately 19.89% to the closing price of HK$0.39 per Share as quoted on the Stock Exchange on 15 July 2025, being the date of the Subscription Agreements; and

(ii) a premium of approximately 22.99% to the average closing price per Share of HK$0.254 as quoted on the Stock Exchange for the last five consecutive trading days immediately preceding the date of the Subscription Agreements.

Each of Revised Subscription Price A and Revised Subscription Price B was negotiated on an arm's length basis between the Company and the respective Subscribers with reference to the current market conditions, prevailing market price and recent trading volume of the Shares.

The gross proceeds from Subscription A will be approximately HK$18,744,000 based on Revised Subscription Price A. The net proceeds from Subscription A, after deduction of the relevant expenses of approximately HK$200,000, will amount to approximately HK$18,544,000, representing a net subscription price of approximately HK$0.309 per Subscription Share A.

The gross proceeds from Subscription B will be approximately HK$9,372,000 based on Revised Subscription Price B. The net proceeds from Subscription B, after deduction of the relevant expenses of approximately HK$100,000, will amount to approximately HK$9,272,000, representing a net subscription price of approximately HK$0.309 per Subscription Share B.

Use of proceeds

Subject to completion of the Subscriptions, the gross proceeds and net proceeds (after deducting all the relevant costs and expenses) from the issue of the Subscription Shares will be approximately HK$28,116,000 and approximately HK$27,816,000, respectively. The Company intends to use such net proceeds for the general working capital of the Group.

The Board confirms that the above supplemental information does not affect other information contained in the Announcement and save as disclosed above, all other information set out in the Announcement remain unchanged.

RESUMPTION OF TRADING

At the request of the Company, trading in the Shares on the Stock Exchange was halted with effect from 9:00 a.m. on Wednesday, 16 July 2025 pending the release of this announcement. An application has been made by the Company to the Stock Exchange for the resumption of trading in the Shares with effect from 9:00 a.m. on Thursday, 17 July 2025.

By order of the Board
Innovative Pharmaceutical Biotech Limited
Yeung Yung
Chairman

Hong Kong, 16 July 2025

As at the date of this announcement, the Board comprises Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkang, Tim (independent non-executive Director), and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: www.ipb.asia and www.irasia.com/listco/hk/ipb.